Management of the metabolic syndrome

American Journal of the Medical Sciences

Volumn 330, Issue 6, 2005, Pages 343-351

  Hafidh, Saad ^a   Senkottaiyan, Neelavathi ^a   Villarreal, Daniel ^b   Alpert, Martin A ^a  

^a ST JOHN S MERCY MEDICAL CENTER   (United States)

^b SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

Author keywords

Atherogenic dyslipidemia; Central obesity; Hyperglycemia; Metabolic syndrome; Raised blood pressure

Indexed keywords

ACETYLSALICYLIC ACID; AMLODIPINE; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BEZAFIBRATE; CAPTOPRIL; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOCOSAHEXAENOIC ACID; EZETIMIBE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FISH OIL; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ICOSAPENTAENOIC ACID; INSULIN; LISINOPRIL; LOSARTAN; METFORMIN; NICOTINIC ACID; OMEGA 3 FATTY ACID; RAMIPRIL; SIBUTRAMINE; SULFONYLUREA; TETRAHYDROLIPSTATIN; THIAZIDE DIURETIC AGENT; TROGLITAZONE;

ABDOMEN; AEROBIC EXERCISE; ATHEROGENESIS; ATHEROSCLEROSIS; BLOOD PRESSURE MEASUREMENT; CALORIC RESTRICTION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONFERENCE PAPER; DIABETES MELLITUS; DIET RESTRICTION; DIET THERAPY; DRUG EFFICACY; DRUG RELEASE; DRUG SAFETY; DYSLIPIDEMIA; FLUSHING; GLUCOSE BLOOD LEVEL; HEART INFARCTION; HUMAN; HYPERCALCIURIA; HYPERGLYCEMIA; HYPERTRIGLYCERIDEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; LIFESTYLE; LOW DRUG DOSE; LOW FAT DIET; MEDITERRANEAN DIET; METABOLIC DISORDER; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PROGNOSIS; RISK FACTOR; SIDE EFFECT; STROKE; UREMIA; VASCULAR DISEASE; WAIST CIRCUMFERENCE;

EID: 29244445985     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000441-200512000-00013     Document Type: Conference Paper

References (89)

1. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005;365:1415-28.
2. Garber AJ. The metabolic syndrome. Med Clin North Am 2004;88:837-46.
3. Zieve FJ. The metabolic syndrome: diagnosis and treatment. Clin Cornerstone 2004;6:1-12.
4. Miranda PJ, DeFronzo RA, Califf RM, et al. Metabolic syndrome: definition, pathophysiology, and mechanisms. Am Heart J 2005;149:44-5.
5. Lakka HM, Laaksonen DE, Lakka TA, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002;288:2709-16.
6. Grundy SM, Brewer HB Jr., Cleeman JI, et al. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004;109: 433-8.
7. Malik S, Wong ND, Franklin SS, et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation 2004;110:1245-50.
8. Wilson PWF, Kannel WB, Silbershatz H, et al. Clustering of metabolic factors and coronary heart disease. Arch Intern Med 1999;159:1104-9.
9. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report. Circulation 2002;106:3143-421.
10. Lamon-Fava S, Wilson PWF, Schaefer EJ. Impact of body mass index on coronary heart disease risk factors in men and women. The Framingham Offspring Study. Arterioscler Thromb Vasc Biol 1996;16:1509-15.
11. World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications: Report of a WHO Consultation; Part 1: Diagnosis and classification of diabetes mellitus. 1999. Available at: http://whqlibdoc. who.int/hq/1999/WHO_NCD_NCS_99.2.pdf. Accessed August 4, 2005.
12. Einhorn D, Reaven GM, Cobin RH, et al. American College of Endocrinology position statement on the insulin resistance syndrome. Endocr Pract 2003;9:237-52.
13. Sutherland J, McKinnley B, Eckel RH. The metabolic syndrome and inflammation. Metabolic Syndr Rel Disord 2004;2:82-104.
14. Ridker PM, Buring JE, Cook NR, et al. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events an 8-year follow-up of 14,719 initially healthy American women. Circulation 2003;107:391-7.
15. Sattar N, Gaw A, Scherbakova O, et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 2003;108:414-19.
16. Mavri A, Stegnar M, Krebs M, et al. Impact of adipose tissue on plasma plasminogen activator inhibitor-1 dieting obese women. Arterioscler Thromb Vasc Biol 1999;19:1582-87.
17. Eliasson B, Attvall S, Taskinen MR, et al. The insulin resistance syndrome in smokers is related to smoking habits. Arteriorscler Thromb 1994;14:1946-50.
18. Wagh A, Stone NJ. Treatment of the metabolic syndrome. Expert Rev Cardiovasc Ther 2004;2:213-281.
19. Stone NJ. Focus on lifestyle change and the metabolic syndrome. Endocrinol Metab Clin North Am 2004;493-508.
20. Clinical guidelines on the identification, evaluation and treatment of overweight and obesity in adults - the evidence report. National Institues of Health. Obes Res 1998;2(Suppl 6):51S-209S.
21. Grundy SM, Hansen B, Smith SC Jr., et al. Clinical management of metabolic syndrome: report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management. Circulation 2004;109:551-6.
22. Grundy SM, Abate N, Chandalia M. Diet composition and the metabolic syndrome: what is the optimal fat intake? Am J Med. 2002;113:255-95.
23. Carr DB, Utzschneider KM, Hull RL, et al. Intra-abdominal fat is a major determinant of the National Cholesterol Education Program Adult Treatment Panel III criteria for the metabolic syndrome. Diabetes 2004;53:2087-94.
24. Krauss RM, Eckel RH, Howard B, et al. AHA dietary guidelines: revision 2000. A statement for healthcare professionals from the Nutrition Committee of the American Heart Association. Circulation 2000;102:2284-99.
25. Wing RR, Hill JO. Successful weight loss maintenance. Annu Rev Nutr 2001;21:323-41.
26. Bravata DM, Sanders L, Huang J, et al. Eficacy and safety of low carbohydrate diets: a systemic review. JAMA 2003;289:1837-50.
27. Samaha FF, Iqbal N, Seshadri P, et al. A low-carbohydrate as compared with a low-fat diet in severe obesity. N Engl J Med 2003;348:2074-81.
28. Brehm BJ, Seeley RJ, Daniels SR, et al. A randomized trial comparing a very low carbohydrate diet and a calorie-restricted low-fat diet on body weight and cardiovascular risk factors in healthy women. J Clin Endocrinol Metab 2003;88:1617-23.
29. Foster GD, Wyatt HR, Hill JO, et al. A randomized trial of a low-carbohydrate diet for obesity. N Engl J Med 2003;348:2082-90.
30. Ornish DBS, Scherwitz LW, Billings JH, et al. Can lifestyle changes reverse coronary heart disease? The Lifestyle Heart Trial. Lancet 1990;336:129-33.
31. Koertge J, Weidner G, Elliott-Eller M, et al. Improvement in medical risk factors and quality of life in women and men with coronary artery disease in the Multicenter Lifestyle Demonstration Project. Am J Cardiol 2003;91:1316-22.
32. Watts GF, Lewis B, Brunt JN, et al. Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St. Thomas Atherosclerosis Regression Study (STARS). Lancet 1992;339:563-9.
33. Poppitt SD, Keogh GF, Prentice AM, et al. Long-term effects of ad libitum low-fat, high-carbohydrate diets on body weight and serum lipids in overweight subjects with metabolic syndrome. Am J Clin Nutr 2002;75:11-20.
34. Garg A. High-monounsaturated-fat diets for patients with diabetes mellitus: a meta-analysis. Am J Clin Nutr 1998;67:577S-82S.
35. Esposito K, Marfella R, Ciotola M, et al. Effect of a Mediterranean-style diet on endothelial dysfunction and markers of vascular inflammation in the metabolic syndrome: a randomized trial. JAMA 2006;292:1440-6.
36. Klein S, Sheard NF, Pi-Sunyer X, et al. Weight management through lifestyle modification for the prevention and management of type 2 diabetes: rationale and strategies. A statement of the American Diabetes Association, the North American Association for the study of Obesity, and the American Society for Clinical Nutrition. Am J Clin Nutr 2004;80:257-60.
37. Thompson PD, Buchner D, Pina IL, et al. Exercise and physical activity in the prevention and treatment of atherosclerotic cardiovascular disease: a statement from the Council on Clinical Cardiology (Subcommittee on Exercise, Rehabilitation and Prevention) and the Council on Nutrition, Physical Activity, and Metabolism (Subcommittee on Physical Activity). Circulation 2003;107:3109-16.
38. US Department of Health and Human Services. Physical activity and health: a report of the Surgeon General. Atlanta, GA: US Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, 1996.
39. Katzmarzyk PT, Leon AS, Wilmore JH, et al. Targeting the metabolic syndrome with exercise: evidence from the HERITAGE Family Study. Med Sci Sports Exerc 2003;35:1703-9.
40. Katzel LI, Bleecker ER, Colman EG, et al. Effects of weight loss vs aerobic exercise training on risk factors for coronary disease in healthy, obese, middle-aged and older men. A randomized controlled trial. JAMA 1995;27:1915-21.
41. Hollander PA, Elbein SC, Hirsch IB, et al. Role of orlistat in the treatment of obese patients with type 2 diabetes: a 1-year randomized double-blind study. Diabetes Care 1998;21:1288-94.
42. Lee WJ, Huang MT, Wang W, et al. Effects of obesity surgery on the metabolic syndrome. Arch Surg 2004;139:1088-92.
43. Pan X, Li G, Hu Y, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care 1997;20:537-44.
44. Diabetes Prevention Program Research Group. Reduction n the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-103.
45. Tuomilehto J, Lindstrom J, Eriksson JG, et al. for the Finnish Diabetes Prevention Study Group.Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344:1342-50.
46. Liao D, Asberry PJ, Shofer JB, et al. Improvement of BMI, body composition, and body fat distribution with lifestyle modification in Japanese Americans with impaired glucose tolerance. Diabetes Care 2002;25:1504-10.
47. Anderssen SA, Hjermann I, Urdal P, et al. Improved carbohydrate metabolism after physical training and dietary intervention in individuals with the atherothrombogenic syndrome. Oslo Diet and Exercise Study (ODES). A randomized trial. J Intern Med 1996;240:203-9.
48. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in over-weight patients with type 2 diabetes. Lancet 1998;352:854-65.
49. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403.
50. Buchanan TA, Xiang AH, Peters RK, et al. Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes 2002;51:2796-803.
51. Freed MI, Ratner R, Marcovina SM, et al. Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in type 2 diabetes mellitus. Am J Cardiol 2002;90:947-52.
52. Grundy S. Small LDL atherogenic dyslipidemia and the metabolic syndrome. Circulation 1997;95:1-4.
53. Vakkilainen J, Steiner G, Ansquer J-C, et al. Relationships between low-density lipoprotein particle size, plasma lipoproteins and progression of coronary artery disease: the Diabetes Atherosclerosis Intervention Study (DAIS). Circulation 2003;107:1733-37.
54. Jeppesen J, Hein HO, Suadicani P, et al. High triglycerides and low HDL cholesterol and blood pressure and risk of ischemic heart disease. Hypertension 2000;36:226-32.
55. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227-39.
56. Knopp RH, Walden CE, Retzlaff BM, et al. Long-term cholesterol-lowering effects of 4 fat-restricted diets in hypercholesterolemic and combined hyperlipidemic men. The Dietary Alternatives Study. JAMA 1998;279:1345-6.
57. Knopp RH, Retzlaff B, Walden C, et al. One-year effects of increasingly fat-restricted, carbohydrate-enriched diets on lipoprotein levels in free-living subjects. Proc Soc Exp Biol Med 2000;225:191-9.
58. Sacks FM, Katan M. Randomized clinical trials on the effects of dietary fat and carbohydrate on plasma lipoproteins and cardiovascular disease. Am J Med 2002;113:13-24.
59. Davidson MH. Combination therapy for dyslipidemia: safety and regulatory considerations. Am J Cardiol 2002;90:50K-60K.
60. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 1999;341:410-8.
61. Chang JT, Staffa JA, Parks M, et al. Rhabdomyolysis with HMG-CoA reductase inhibitors and gemfibrozil combination therapy. Pharmacoepidemiol Drug Saf 2004;13:417-26.
62. Vega GL, Ma PTS, Cater NB, et al. Effects of adding fenofibrate (200 mg/day) to simvastatin (10 mg/day) in patients with combined hyperlipidemia and metabolic syndrome. Am J Cardiol 2003;91:956-60.
63. Bergman AJ, Murphy G, Burke J, et al. Simvastatin does not have a clinically significant pharmacokinetic interaction with fenofibrate in humans. J Clin Pharmacol 2004;44:1054-62.
64. Israeli Society for Prevention of Heart Attack. Secondary Prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention Study. Circulation 2000;102:21-7.
65. Knopp RH, Alagona P, Davidson M, et al. Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia. Metabolism 1998;47:1097-104.
66. Guyton JR, Blazing MA, Hagar J, et al. Extended-release niacin vs. gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol. Arch Intern Med 2000;160:1177-84.
67. Grundy SM, Vega GL, McGovern ME, et al. Efficacy, safety and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of Diabetes Control and Evaluation of the Efficacy of Niaspan Trial. Arch Intern Med 2002;162:1568-76.
68. Delarue J, LeFoll C, Corporeau C, et al. N-3 long chain polyunsaturated fatty acids: A nutritional tool to prevent insulin resistance associated to type 2 diabetes and obesity? Reprod Nutr Dev 2004;44:289-99.
69. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. Hypertension 2003;42:1206-52.
70. Appel LJ, Moore FJ, Obarzanek E, et al. A clinical trial of the effects of dietary patterns on blood pressure. N Engl J Med 1997;336:1117-24.
71. Su HY, Sheu WH, Chin HM, et al. Effect of weight loss on blood pressure and insulin resistance in normotensive and hypertensive obese individuals. Am J Hypertens 1995;8:1067-71.
72. Reisin E, Abel R, Modan M, et al. Effect of weight loss without salt restriction on the reduction of blood pressure in overweight hypertensive patients. N Engl J Med 1978;298:1-6.
73. Sacks FM, Svetkey LP, Vollmer WM, et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. N Engl J Med 2001;344:3-10.
74. Vollmer WM, Sacks FM, Ard J, et al. Effects of diet and sodium intake on blood pressure: subgroup analysis of the DASH-Sodium Trial. Ann Intern Med 2001;135:1019-28.
75. Hsio-Yueh S, Wayne HHS, Hue-Mim LC, et al. Effect of weight loss on blood pressure and insulin resistance in normotensive and hypertensive obese individuals. Am J Hyperten 1995;8:1067-71.
76. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145-53.
77. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic. The Antihypertensive and Lipid-Lowering treatment of prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981-97.
78. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in Type 2 diabetes. UK Prospective Diabetes Study Group. BMJ 1998;317:713-20.
79. Lindholm LH, Ibsen H, Dahlof B, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For End point reduction in hypertension study (LIFE): a randomized trial against arenolol. Lancet 2002;359:1004-10.
80. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with Type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-9.
81. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to Type 2 diabetes. N Engl J Med 2001;345:851-60.
82. van Dielen FM, Buurman WA, Hadfoune M, et al. Macrophage inhibitor factor, plasminogen activator inhibitor-1, other acute phase proteins, and inflammatory mediators normalize as a result of weight loss in morbidly obese subjects treated with gastric restrictive surgery. J Clin Endocrinol Metab 2004;89:4062-68.
83. Colwell JA. Antiplatelet agents for the prevention of cardiovascular disease in diabetes mellitus. Am J Cardiovasc Drugs 2004;4:87-106.
84. Wilson PW. Insulin resistance syndrome and the rothrombotic state: a Framingham perspective. Endocr Pract 2003;9 (Suppl 2):50-2.
85. Ridker PM, Cushman M, Stampfer MJ, et al. Inflammation, aspirin and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997;336:973-9.
86. Wannamethee SG, Lowe GD, Whincup PH, et al. Physical activity and hemostatic and inflammatory variables in elderly men. Circulation 2002;105:1785-90.
87. Nesto R. C-reactive protein, its role in inflammation, Type 2 diabetes and cardiovascular disease, and the effects of insulin-sensitizing treatment with thiazolidinediones. Diabet Med 2004;21:810-7.
88. Pischon T, Hankinson SE, Hotamisligil GS, et al. Leisure-time physical activity and reduced plasma levels of obesity-related inflammatory markers. Obes Res 2003;11:1055-64.
89. Jialal I, Stein D, Balis D, et al. Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation 2001;103:1933-5.